This site and its contents are intended to assist current and potential investors in making investment decisions. Small Pharma is a research and development company with currently no approved medicines. Therefore, the information provided on this site is not intended for healthcare professionals, patients, or members of the public.

 

Everyone deserves the option of better mental health

Small Pharma is a biotechnology company researching and developing short-acting psychedelics with therapy for under-served mental health conditions.

Investor Deck

Everyone deserves the option of better mental health

Small Pharma is a biotechnology company researching and developing short-acting psychedelics with therapy for under-served mental health conditions.

Investor Deck

Today’s antidepressants leave a third of patients behind. This mental health epidemic needs solutions, not wishful thinking.

Peter Rands

Co-Founder, Small Pharma

We’re on a mission to fast track the development of new therapies for patients affected by depression.

People deserve mental health therapies that are well-tolerated, work quickly and have long lasting effects, tackling the root causes rather than numbing the symptoms.

Who we are,
what we do

Find out more about our story and meet the team behind Small Pharma

‘We do have to start looking for a completely different approach, and try something completely out of the box.’

Dr Carol Routledge, CMSO

It has been a real pleasure working with Small Pharma since the launch of Drug Science’s Medical Psychedelics Working Group in July 2020. Small Pharma have been a partner since the beginning, together we have achieved much and have far-reaching plans for the future.
Prof Jo Neill
Scientific Committee at Drug Science
Traditional talk therapy can be extremely expensive and for some it takes years to process their psychological issues. Often it is those rare experiential moments when a re-enactment of old wounds surfaces that provide a real shift in the therapeutic process. Psychedelics can provide those experiential moments and thus hold great potential in catalysing therapy.
Michelle Baker Jones
Study Therapist on Small Pharma's clinical trial
Small Pharma’s endeavour to test psychedelic therapy for depression is not only interesting and timely but also very important. Their ambitious research program has the potential to make a positive difference for patients suffering depression.
Dr David Erritzoe
Clinical Director at the Centre for Psychedelic Research

Our approach

We’re committed to the safe trial of new medicines through a visionary drug development approach.

By driving innovation on known compounds, we aim to accelerate the development of new potential optimised medicines for treating challenging conditions underserved by existing treatments.

ayahuasca tree with sunlight in the background

Psychedelic therapies

Psychedelic based treatments may have potential as antidepressant therapies.

They may have benefits over existing treatments. Our core drug pipeline harnesses the potential of a short acting psychedelic, a naturally occurring compound found in plants and animals, which is believed to have possible medicinal properties.

Research & trials

See how Small Pharma is unlocking the potential of psychedelic medicines through groundbreaking and accelerated R&D

Representative example of Small Pharma DMT Molecule

Years of R&D development

Medicines in development

Active Phase I/IIa clinical trial

About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

Get Small Pharma
Investor Updates

    Investor Deck

    Follow us: